AI-generated content for informational purposes only. Not financial advice. Always do your own research.

About

Danaher Corporation (DHR) is a diversified science and technology conglomerate operating across life sciences, diagnostics, and environmental solutions segments. The company is renowned for its proprietary Danaher Business System (DBS), a continuous improvement methodology that drives operational excellence and margin expansion across its portfolio of businesses. DHR's focus on high-growth, high-margin life sciences end markets and its disciplined capital allocation make it a top-quality industrial compounder.

Healthcare Stocks

Danaher provides critical instruments, diagnostics, and services to healthcare customers worldwide through its life sciences and diagnostics segments, which together generate the majority of the company's revenue and profits.

Industrial Stocks

Danaher is a diversified industrial conglomerate renowned for its proprietary Danaher Business System, a lean manufacturing and continuous improvement methodology that has driven industry-leading margins and returns on invested capital across its portfolio of businesses.

Key Financials DHR

Price $212.58
Change (1D) -1.10%
Change (30D) -7.14%
Change (60D) -3.57%
Change (90D) +0.41%
Change (180D) +12.47%
Change (1Y) +5.14%
Change (5Y) +1.18%
P/E Ratio 36.84
EPS (TTM) $5.77
52-Week Range $171.00 โ€” $242.80
50-Day MA $228.34
Volume 5.29M

Data updated Feb 15 ยท Source: Twelve Data

4.3 2 reviews

AI Reviews

๐Ÿค–
4.0 /5

Danaher is a premier life sciences and diagnostics company following its 2023 spin-off of Veralto, now focused squarely on biotechnology, diagnostics, and environmental solutions. The company's renowned Danaher Business System (DBS) drives continuous operational improvement, giving it a durable competitive moat.

The bull case centers on Danaher's dominant positions in bioprocessing (Cytiva, Pall), diagnostics (Beckman Coulter, Leica), and its proven M&A playbook. Post-COVID normalization headwinds in bioprocessing appear to be fading, setting up a potential earnings recovery cycle. The 180-day return of +12.5% suggests improving sentiment.

The bear case involves the elevated P/E of 36.8x against modest EPS of $5.77, demanding significant growth acceleration to justify the premium. The stock trades roughly 12% below its 52-week high and below its 50-day moving average, indicating near-term technical weakness. Five-year returns of just 1.2% highlight a prolonged period of underperformance relative to the broader market.

Danaher remains a high-quality compounder, but investors should be patient and consider dollar-cost averaging at current valuations rather than deploying aggressively.

Category Ratings

Healthcare Stocks
4.1
Industrial Stocks
3.8
Feb 15, 2026
AI-Generated Review Generated via Anthropic API. This is an automated evaluation, not a consumer review. Learn more
๐Ÿค–
4.6 /5

Danaher Corporation (DHR) stands as a premier 'picks and shovels' play in the life sciences and diagnostics sectors. Renowned for the Danaher Business System (DBS), the company excels at operational efficiency and integrating acquisitions to drive margin expansion.

The stock currently trades at a premium P/E ratio of 33.38, reflecting its status as a high-quality compounder with significant recurring revenue from consumables. While the long-term thesis is supported by secular trends in genomic medicine and biologics, near-term risks persist regarding inventory destocking among bioprocessing clients.

Trading near $220, DHR is positioned comfortably between its 52-week range of $171 and $243. For investors, Danaher offers defensive growth characteristics and a wide competitive moat, though the elevated valuation demands continued execution. It remains a foundational holding for investors seeking exposure to healthcare innovation without single-drug binary risk.

Category Ratings

Healthcare Stocks
4.7
Industrial Stocks
4.4
Feb 12, 2026
AI-Generated Review Generated via Google API. This is an automated evaluation, not a consumer review. Learn more
Danaher Screenshot

Added: Feb 11, 2026

danaher.com